DR. THOMAS NAJARIAN, M.D.
Osteopathic Medicine at Sunset Dr, San Luis Obispo, CA
License number
California G86035
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California G86035
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
2280 Sunset Dr STE D, San Luis Obispo, CA 93402
Phone
(805) 528-0650
(805) 528-1690 (Fax)
(805) 528-1690 (Fax)
Personal information
See more information about THOMAS NAJARIAN at radaris.comName
Address
Phone
178 Montara Dr #139, Aliso Viejo, CA 92656
744 11Th St, Manhattan Beach, CA 90266
744 11Th St, Manhattan Beach, CA 90266
505 Avon St, Burbank, CA 91505
5050 Ashlan Ave, Fresno, CA 93727
Organization information
See more information about THOMAS NAJARIAN at bizstanding.comThomas Najarian MD
2280 Sunset Dr, Los Osos, CA 93402
Industry:
Internist
Phone:
(805) 528-0650 (Phone)
Thomas Najarian
Professional information
Thomas Najarian, Los Osos CA
Specialties:
Internist
Address:
2280 Sunset Dr, Los Osos, CA 93402
Education:
Harvard Medical School - Doctor of Medicine
VA Boston Healthcare System-Jamaica Plain Campus - Fellowship - Hematology
VA Boston Healthcare System-Jamaica Plain Campus - Residency - Internal Medicine
VA Boston Healthcare System-Jamaica Plain Campus - Fellowship - Hematology
VA Boston Healthcare System-Jamaica Plain Campus - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Treatment Of Pulmonary Hypertension With Carbonic Anhydrase Inhibitors
US Patent:
8071557, Dec 6, 2011
Filed:
Jun 13, 2007
Appl. No.:
11/818306
Inventors:
Thomas Najarian - Los Osos CA, US
Peter Y. Tam - Redwood City CA, US
Leland F. Wilson - Menlo Park CA, US
Craig Peterson - Mountain View CA, US
Peter Y. Tam - Redwood City CA, US
Leland F. Wilson - Menlo Park CA, US
Craig Peterson - Mountain View CA, US
Assignee:
Vivus, Inc. - Mountain View CA
International Classification:
A61K 31/7024, A61K 31/4985, A61K 31/137
US Classification:
514 23, 514249, 514250
Abstract:
This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.
Treatment Of Pulmonary Hypertension With Carbonic Anhydrase Inhibitors
US Patent:
8536138, Sep 17, 2013
Filed:
Dec 5, 2011
Appl. No.:
13/311476
Inventors:
Thomas Najarian - Los Osos CA, US
Peter Y. Tam - Redwood City CA, US
Leland F. Wilson - Menlo Park CA, US
Craig Peterson - Mountain View CA, US
Peter Y. Tam - Redwood City CA, US
Leland F. Wilson - Menlo Park CA, US
Craig Peterson - Mountain View CA, US
Assignee:
Vivus, Inc. - Mountain View CA
International Classification:
A61K 31/53, A61K 31/407, A61K 31/506, A61K 31/513, A61K 31/519, A61K 31/7048, A61P 11/00, A61K 31/137
US Classification:
514 23, 514243, 514250, 5142611, 514269, 514275
Abstract:
This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.
Combination Therapy For Effecting Weight Loss And Treating Obesity
US Patent:
7553818, Jun 30, 2009
Filed:
Mar 20, 2006
Appl. No.:
11/385198
Inventors:
Thomas Najarian - Los Osos CA, US
Assignee:
Vivus, Inc. - Mountain View CA
International Classification:
A61K 31/135, A61K 31/70
US Classification:
514 23, 514646
Abstract:
The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e. g. , phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e. g. , topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
Combination Therapy For Effecting Weight Loss And Treating Obesity
US Patent:
7674776, Mar 9, 2010
Filed:
Mar 20, 2006
Appl. No.:
11/385233
Inventors:
Thomas Najarian - Los Osos CA, US
Assignee:
Vivus, Inc. - Mountain View CA
International Classification:
A61K 31/135, A61K 31/70
US Classification:
514 23, 514646
Abstract:
The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e. g. , phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e. g. , topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
Escalating Dosing Regimen For Effecting Weight Loss And Treating Obesity
US Patent:
8580299, Nov 12, 2013
Filed:
Jun 9, 2009
Appl. No.:
12/481548
Inventors:
Thomas Najarian - Los Osos CA, US
Peter Y. Tam - Redwood City CA, US
Leland F. Wilson - Menlo Park CA, US
Peter Y. Tam - Redwood City CA, US
Leland F. Wilson - Menlo Park CA, US
Assignee:
Vivus, Inc. - Mountain View CA
International Classification:
A61K 9/48
US Classification:
424451, 424490, 514 23, 514646, 514455
Abstract:
The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e. g. , in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.
Combination Therapy For Effecting Weight Loss And Treating Obesity
US Patent:
2010010, Apr 29, 2010
Filed:
Jan 6, 2010
Appl. No.:
12/683353
Inventors:
Thomas Najarian - Los Osos CA, US
International Classification:
A61K 31/35, A61K 31/137
US Classification:
514455, 514654
Abstract:
The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss.The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
Treatment With Cholinergic Agonists
US Patent:
2011019, Aug 11, 2011
Filed:
Oct 5, 2010
Appl. No.:
12/898241
Inventors:
Thomas NAJARIAN - Los Osos CA, US
Kathyrn Susan UNKEL - Los Osos CA, US
Kathyrn Susan UNKEL - Los Osos CA, US
International Classification:
A61K 31/439, A61K 31/4178, A61K 31/557, A61P 15/00, A61P 35/00, A61P 13/02
US Classification:
514278, 514397, 514573
Abstract:
Methods of treating disorders with cholinergic agonists for example, muscarinic receptor agonists such as pilocarpine and cevimeline are provided. In particular, methods of treating and/or preventing interstitial cystitis, yeast infections, urinary tract infections, atrophic vaginitis, vaginal dryness, and sexual dysfunction associated with vaginal dryness by administering a cholinergic agonist to the subject suffering from the disorders are provided. In addition, intra-vaginal administration of cholinergic agonists such as muscarinic receptor agonists to patients suffering from interstitial cystitis, vaginal dryness, and sexual dysfunction associated with vaginal dryness is also provided.
Combination Therapy For Effecting Weight Loss And Treating Obesity
US Patent:
7659256, Feb 9, 2010
Filed:
Mar 20, 2006
Appl. No.:
11/385199
Inventors:
Thomas Najarian - Los Osos CA, US
Assignee:
Vivus, Inc. - Mountain View CA
International Classification:
A61K 31/135, A61K 31/70
US Classification:
514 23, 514646
Abstract:
The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e. g. , phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e. g. , topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
Novel Topiramate Compositions And An Escalating Dosing Strategy For Treating Obesity And Related Disorders
US Patent:
2009030, Dec 10, 2009
Filed:
Jun 9, 2008
Appl. No.:
12/135953
Inventors:
Thomas Najarian - Los Osos CA, US
Peter Y. Tam - Redwood City CA, US
Leland F. Wilson - Menlo Park CA, US
Peter Y. Tam - Redwood City CA, US
Leland F. Wilson - Menlo Park CA, US
International Classification:
A61K 31/357, A61P 3/10, A61K 9/48, A61K 9/52, A61P 3/04
US Classification:
424457, 514455, 424451
Abstract:
The present invention is drawn to novel topiramate compositions as well as methods for treating obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention also features a pharmaceutical composition that includes, e.g., topiramate alone or in combination with a sympathomimetic agent and a novel escalating dosing strategy for administering such compositions.
Osteopathic Medicine licenses in California
BARRY EIBSCHUTZ, M.D. INC, Osteopathic Medicine, 1551 Bishop St SUITE 230, San Luis Obispo, CA 93401